Trial Profile
A Randomized, Open Label Study to Evaluate the Pleiotropic Effects of Azilsartan Medoxomil 40 and 80 mg for 12 Weeks Over Metabolic Markers in Patients With Hypertension, Obesity or Type 2 Diabetes Mellitus
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Azilsartan medoxomil (Primary)
- Indications Hypertension; Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 15 Sep 2014 New trial record